Ameriprise’s GT Biopharma GTBP Stock Holding History

Ameriprise’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-486	Closed	-$44K	–	3972
2021 Q4	$44K	Buy	+486	New	+$72.7K	﹤0.01%	3908

Other funds holding GTBP

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ameriprise's GTBP Position: Q1 2022 in Review

Ameriprise sold out of GT Biopharma (GTBP) in Q1 2022, closing a stake of 486 shares — an estimated $44K sold.

Ameriprise first reported a position in GTBP in Q4 2021 and held it in 1 quarter. The position peaked at $44K in Q4 2021. 57 funds tracked by Wall St. Rank hold GTBP as of Q1 2022.

Ameriprise reported no remaining GT Biopharma position as of Q1 2022 after selling out during the quarter.
Ameriprise sold 486 GT Biopharma shares in Q1 2022, an estimated $44K.
Ameriprise first reported a position in GT Biopharma in Q4 2021 and held it in 1 quarter.
Ameriprise's GT Biopharma position peaked at $44K in Q4 2021.
57 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2022.

Based on Ameriprise's 13F filing for Q1 2022, filed 16 May 2022.